CU Technology and Discovery News

Donated blood has a shelf life. A new test tracks how it's aging

Daniel Corbin Leonard — Mon, 26 Jan 2026 20:18:52 +0000

Donated blood has a shelf life. A new test tracks how it's aging Daniel Corbin … Mon, 01/26/2026 - 13:18

CU ��ý�� Today—University of Colorado researchers have developed a fast, easy test that could help blood centers and hospitals monitor the quality of stored red blood cells. The palm-sized, chip-based device uses surface acoustic waves to assess cell aging, with the goal of improving transfusion outcomes and better allocating high-quality blood to patients.

Partnering Opportunities with CU Technologies

Venture Partners manages a portfolio of over 1,000 technologies from university investigators and manages licensing partnerships with companies of all sizes—from startups to the Fortune 500—to bring these inventions to market. Discover how CU’s solutions can power your next breakthrough.

Explore Opportunities

Off

Traditional

White

LeCun calls LLMs a dead end, but two CU Denver researchers offer a revolutionary way forward

Daniel Corbin Leonard — Fri, 09 Jan 2026 17:10:19 +0000

LeCun calls LLMs a dead end, but two CU Denver researchers offer a revolutionary way forward Daniel Corbin … Fri, 01/09/2026 - 10:10

Colorado AI News—A PhD student and an associate professor at CU Denver are trying to make today's language models more inventive without letting them drift into nonsense. They landed in MIT Technology Review's "What's next for AI in 2026" with a deceptively simple question: Can today's AI language models generate genuinely new ideas without turning creativity into nonsense?

More at Colorado AI News More at MIT Technology Review Read the Paper at arXiv

Partnering Opportunities with CU Technologies

Explore Opportunities

Off

Traditional

White

CU ��ý�� pre-seed investment fuels cancer ‘moonshot’ spinout Illumen Therapeutics

Daniel Corbin Leonard — Tue, 06 Jan 2026 21:18:56 +0000

CU ��ý�� pre-seed investment fuels cancer ‘moonshot’ spinout Illumen Therapeutics Daniel Corbin … Tue, 01/06/2026 - 14:18

Heather Hansen

In an ongoing effort to bridge a pervasive investment gap in innovation funding, the ��ý�� has awarded pre-seed funding to Illumen Therapeutics, developing cancer treatments based on discoveries from startup co-founder Roy Parker’s lab at CU ��ý��.

Venture Partners at CU ��ý�� recently created a pre-seed investment mechanism to help bridge the so-called “valley of death” between research and commercialization, where even high-potential start-ups can sometimes get lost, said Bryn Rees, senior associate vice chancellor for innovation and partnerships. “When somebody creates an innovation with broad potential to be translated out into a new venture, there is now funding to support the earliest stages of that new company,” said Rees. “This was a missing piece.”

The point of the pre-seed funding is “to bridge that gap between promise and follow-on investments,” he said. “We are building upon the brilliance of our faculty; they’re the ones who are saying, ‘I am trying to solve the hardest problems in the world’.”

What we do for university innovators

Venture Partners helps researchers, inventors and creators at CU take their groundbreaking discoveries every step from intellectual property (IP) management to market launch.

Learn More

Pre-seed investments are made in promising companies translating CU ��ý�� innovations through CU ��ý�� License Equity Holdings (CUBLEH), a nonprofit entity separate from the university but run in partnership with it. Recognizing that a compelling startup could spin out from particular research or innovation is good for the university, researchers and society at-large, said Rees. “This is where the university really is stepping into opportunity and even responsibility to ensure that the products of its research are having that real-world impact,” he said. “This is why the pre-seed investment is so critical.”

The fund is intended to help energized, high-potential startups as they prepare for outside investment, a critical moment on their path to commercialization, said Hannah Nelson, associate director of licensing at Venture Partners. “Pre-seed funding gets placed in companies where we see momentum, an exciting commercial opportunity and a motivated founder, and I think that Illumen Therapeutics has shown all three of those things,” she said. “Another piece of what prioritizes companies for the pre-seed funding is that they’re already at that stage of development where we feel like this funding can unlock follow-on funds to get them to their next big inflection point.”

But what is "commercialization?"

The path to commercialization—also known as "research translation" or "tech transfer"—can be challenging, so Venture Partners unites industry partners, entrepreneurs and investors to help researchers, inventors and creators at the University of Colorado bring their groundbreaking discoveries into the marketplace.

Explore the Path to Commercialization

Arming the ‘guardian of the genome’

Illumen Therapeutics is focused on a cancer treatment ‘moonshot’ that pursues the long-sought ‘holy grail’ of drug development—but with an entirely new approach. That elusive goal revolves around a tumor suppressor gene called p53, dubbed the ‘guardian of the genome’ because it prevents damaged cells from multiplying, which blocks the formation and growth of tumors linked to a wide range of cancers.

“P53 is a key protein mutated in 85 to 95 percent of human cancers, and its loss allows cells to grow in an uncontrolled way,” explained Roy Parker, company co-founder, director of the BioFrontiers Institute and Cech-Leinwand Endowed Chair of CU ��ý�� Biochemistry. “If you could restore p53 function, the hope is that would actually cause the tumors to either die or grow less.”

For several decades, popular strategies to target p53 have focused on blocking gene-inhibiting proteins. “There has been literally billions of dollars spent on this idea trying to target these inhibitors of p53,” said Parker, but all attempts have failed due to unexpected consequences like increased toxicity and a feedback loop that further suppresses p53. “The overall goal of increasing functional p53 is still a really important idea, and we just need ways to do that,” he said.

The leading-edge science behind Illumen Therapeutics, which emerged from the Parker Lab several years ago (including the work of postdoc fellow Siddharth Shukla), is based on a novel strategy to target PARN, an enzyme that affects p53. Inhibiting PARN to enhance functional p53 could potentially treat nearly half of all human tumors in aggressive cancers with limited therapeutic options like colorectal, triple-negative breast, pancreatic and others.“ That seems to be working, so that’s kind of proof of principle that if you could help p53, it might be really useful,” said Parker.

Parker envisions that any new therapeutic developed by Illumen will be used in combination with others to improve their effectiveness and could target subclasses of tumors that function differently than their broader tumor type. “A drug which even treats one subtype of cancer is still really important,” he said. “I’d be thrilled if we could reach that far.”

“We think it’s the key”

Despite the originality of the approach, the work was shelved until 2023, when Nelson connected with Bob Blomquist, a ��ý��-based serial entrepreneur with biosciences expertise, who was looking for ideas with solid commercialization potential. One of the technologies Nelson thought might be a good fit was the PARN-p53 research from Parker’s lab.

Right away, Blomquist knew he wanted to learn more.

“When I met Roy and saw his data, it was like lights and sirens were going off,” he said. “That phenomenal discovery made by Roy’s lab may mean we can restore functional p53–that holy grail of cancer drug development. We think it’s the key.”

Blomquist, a trained geneticist, has spent decades of his business career working in oncology drug discovery, development and commercialization, and the more he dug into the technology, talking with experts, the more promising the innovation seemed. “I reached out to experts at MD Anderson [Cancer Center] and CU Anschutz, and asked, ‘What do you think about this therapeutic strategy?’ And their eyes popped open, and their response was, ‘This could be the breakthrough we’ve been dreaming of’.”

Investor and Partnership Opportunities

Venture Partners seeks entrepreneurs to start new companies, connects investors with high-potential ventures and facilitates collaborations with companies seeking to invest in research or license technologies from the university.

Learn More

Blomquist co-founded Illumen in 2024 and credits both Venture Partners and Parker for helping build the strong team that’s now moving Illumen’s work forward. “The key role Venture Partners plays is so different than other institutions,” said Blomquist. “They really, truly work as a partner, helping to understand the science, how to connect with potential investors, and on and on. It’s a unique, strong and valuable partnership.”

The pre-seed funding is critical to helping Illumen reach its next inflection point, said Blomquist. “Having that investment got us started to de-risk the project, to show that this is a valid target and to duplicate the data, while we work on the rest of the financial raise,” he said

Rees also believes the investment is a solid one. “We have worked closely with the Parker Lab and with Bob for over a year, so we have a certain level of insight into the magnitude of the clinical impact, the strength of the underlying research and the compelling business case here in order to make the investment,” he said. “At the same time, that investment is absolutely necessary to hit those milestones and generate follow-on investor and partner interest.”

The passion behind Illumen is also personal for Blomquist, who lost his wife to triple-negative breast cancer in 2008. “This is why I get up in the morning, to make a difference in people’s lives. I can’t help my late wife, but what if we can help others? What if by developing a treatment with Roy’s technology we could turn treating cancer into a chronic illness? So that’s why I’m motivated to do something,” he said. “We’re all trying to make a difference.”

What Can We Do Together?

Disclose and Protect Your Innovation

Engage in Entrepreneurial Training Programs

Find a Mentor to Advance Your Innovation

Get Funding for Your Innovation

Find Partners and Opportunities for Your Innovation

Explore Investing in and Partnering with CU Researchers

Explore Our Startups Portfolio

Explore Our Technology Portfolio

In an ongoing effort to bridge a pervasive investment gap in innovation funding, the ��ý�� has awarded pre-seed funding to Illumen Therapeutics, developing cancer treatments based on discoveries from startup co-founder Roy Parker’s lab at CU ��ý��.

Off

Traditional

White

WATCH: CU ��ý�� researchers studying pythons to develop weight loss treatment

Daniel Corbin Leonard — Tue, 30 Dec 2025 18:41:11 +0000

WATCH: CU ��ý�� researchers studying pythons to develop weight loss treatment Daniel Corbin … Tue, 12/30/2025 - 11:41

FOX31 Denver—Host Genelle Padilla speaks with Jack Gugel and Thomas Martin, two researchers at the ��ý��, who are studying pythons to develop a weight-loss treatment.

Partnering Opportunities with CU Technologies

Explore Opportunities

FOX31 Denver—Host Genelle Padilla speaks with Jack Gugel and Thomas Martin, two researchers at the ��ý��, who are studying pythons to develop a weight-loss treatment.

Off

Traditional

White

NASA selects a CU ��ý�� lab to build instruments for the moon

Daniel Corbin Leonard — Tue, 16 Dec 2025 19:15:38 +0000

NASA selects a CU ��ý�� lab to build instruments for the moon Daniel Corbin … Tue, 12/16/2025 - 12:15

Denver7—NASA has selected a proposal from CU ��ý�� researchers to design and build instruments that will be deployed by astronauts on the Moon. The instrument suite designed at the Laboratory for Atmospheric and Space Physics (LASP) will analyze lunar dust, which is abrasive like glass and sticks to all surfaces. Lunar dust can damage equipment and harm astronauts if inhaled.

Watch or Read this Story

Partnering Opportunities with CU Technologies

Explore Opportunities

Denver7—NASA has selected a proposal from CU ��ý�� researchers to design and build instruments that will be deployed by astronauts on the Moon. The instrument suite designed at the Laboratory for Atmospheric and Space Physics (LASP) will analyze lunar dust, which is abrasive like glass and sticks to all surfaces. Lunar dust can damage equipment and harm astronauts if inhaled.

Off

Traditional

White

CU ��ý�� lab creates bubble wrap-like window material that traps heat without blocking light

Daniel Corbin Leonard — Fri, 12 Dec 2025 20:18:14 +0000

CU ��ý�� lab creates bubble wrap-like window material that traps heat without blocking light Daniel Corbin … Fri, 12/12/2025 - 13:18

A new, thin insulator has been designed to boost the energy efficiency of windows by blocking heat. Designed by a team from the ��ý��, this invisible window shield material has been dubbed Mesoporous Optically Clear Heat Insulator (MOCHI).

Partnering Opportunities with CU Technologies

Explore Opportunities

Off

Traditional

White

Scientists use ultrasound to soften and treat cancer tumors without damaging healthy tissue

Daniel Corbin Leonard — Mon, 08 Dec 2025 20:23:40 +0000

Scientists use ultrasound to soften and treat cancer tumors without damaging healthy tissue Daniel Corbin … Mon, 12/08/2025 - 13:23

CU ��ý�� Today—Cancer is one of the leading causes of death in the U.S., second only to heart disease. But a new cancer treatment method from CU ��ý�� researchers uses sound waves to soften tumors and could be a potent tool against the disease.

Partnering Opportunities with CU Technologies

Explore Opportunities

Off

Traditional

White

Agami Zero breaks through with magnetic hydrogen advance

Daniel Corbin Leonard — Wed, 03 Dec 2025 19:31:40 +0000

Agami Zero breaks through with magnetic hydrogen advance Daniel Corbin … Wed, 12/03/2025 - 12:31

Renewable And Sustainable Energy Institute—A startup team led by RASEI Fellow Oana Luca, called Agami Zero, has just secured seed funding after winning the 2025 CU Lab Venture Challenge. Their winning idea? A new way to produce hydrogen fuel more efficiently, a key mechanism for decarbonizing our energy economy.

Off

Traditional

White

CU ��ý�� leading $45M in ARPA-H grants for self-healing joints, wound care

Daniel Corbin Leonard — Tue, 02 Dec 2025 19:04:22 +0000

CU ��ý�� leading $45M in ARPA-H grants for self-healing joints, wound care Daniel Corbin … Tue, 12/02/2025 - 12:04

CU ��ý�� College of Engineering & Applied Science—In 2025, CU ��ý�� celebrated its first awards from the Advanced Research Projects Agency for Health (ARPA-H). The new agency within the U.S. Department of Health and Human Services supports transformative health and biomedical breakthroughs. ARPA-H was founded in 2022 with a mission to fast-track “high-impact solutions to society’s most challenging health problems.”

Read the Full Story

Partnering Opportunities with CU Technologies

Explore Opportunities

Off

Traditional

White

Researchers redefine hip arthroscopy with breakthrough surgical device

Daniel Corbin Leonard — Wed, 12 Nov 2025 23:17:28 +0000

Researchers redefine hip arthroscopy with breakthrough surgical device Daniel Corbin … Wed, 11/12/2025 - 16:17

CU ��ý�� College of Engineering and Applied Science—The technology, published in the journal Arthroscopy Techniques, completely transforms arthroscopic procedures in the hip region, making them safer and more efficient than ever before.

Read the Full Story

Partnering Opportunities with CU Technologies

Explore Opportunities

Off

Traditional

White

CU Technology and Discovery News

Donated blood has a shelf life. A new test tracks how it's aging

Partnering Opportunities with CU Technologies

Off

LeCun calls LLMs a dead end, but two CU Denver researchers offer a revolutionary way forward

Partnering Opportunities with CU Technologies

Off

CU ������ý���� pre-seed investment fuels cancer ‘moonshot’ spinout Illumen Therapeutics

But what is "commercialization?"

Arming the ‘guardian of the genome’

“We think it’s the key”

What Can We Do Together?

Off

WATCH: CU ������ý���� researchers studying pythons to develop weight loss treatment

Partnering Opportunities with CU Technologies

Off

NASA selects a CU ������ý���� lab to build instruments for the moon

Partnering Opportunities with CU Technologies

Off

CU ������ý���� lab creates bubble wrap-like window material that traps heat without blocking light

Partnering Opportunities with CU Technologies

Off

Scientists use ultrasound to soften and treat cancer tumors without damaging healthy tissue

Partnering Opportunities with CU Technologies

Off

Agami Zero breaks through with magnetic hydrogen advance

Off

CU ������ý���� leading $45M in ARPA-H grants for self-healing joints, wound care

Partnering Opportunities with CU Technologies

Off

Researchers redefine hip arthroscopy with breakthrough surgical device

Partnering Opportunities with CU Technologies

Off

CU ��ý�� pre-seed investment fuels cancer ‘moonshot’ spinout Illumen Therapeutics

WATCH: CU ��ý�� researchers studying pythons to develop weight loss treatment

NASA selects a CU ��ý�� lab to build instruments for the moon

CU ��ý�� lab creates bubble wrap-like window material that traps heat without blocking light

CU ��ý�� leading $45M in ARPA-H grants for self-healing joints, wound care